Last updated: February 20, 2026
What Does Patent LT2958921 Cover?
Lithuanian patent LT2958921 relates to a pharmaceutical compound or formulation. It claims specific compositions, methods of manufacturing, and potential uses. The patent was filed on April 15, 2014, and published on October 20, 2015.
Key Claims Overview
- Primary Claims: Cover compositions comprising a specific active pharmaceutical ingredient (API) combined with excipients, designed for targeted therapeutic applications.
- Method Claims: Encompass methods of preparing the composition under defined conditions.
- Use Claims: Cover specific medical indications of the composition, such as treatment of a particular disease or condition.
Scope of Claims
The patent's scope encompasses:
- Composition claims with particular ratios of API and excipients.
- Manufacturing processes involving specific steps.
- Methods of administering the formulation for treatment purposes.
- Particular formulations in solid, liquid, or semi-solid forms.
The claims are drafted broadly to include variants of the formulation within defined parameters, ensuring coverage over multiple embodiments.
Patent Claims Breakdown
| Claim Type |
Focus |
Key Elements |
Constraints |
| Composition claims |
API in combination with excipients for therapeutic use |
Specific APIs, excipient types, and ratios |
Ratios must fall within specified ranges |
| Method claims |
Manufacturing process of the pharmaceutical composition |
Step-by-step procedures, processing conditions |
Conditions are explicitly defined to restrict scope |
| Use claims |
Medical indications for the composition |
Target diseases, administration routes |
Limits claims to particular diseases and methods of use |
Patent Landscape Context
Filing and Grant Timeline
| Event |
Date |
Details |
| Filing date |
April 15, 2014 |
Priority date for patent rights |
| Publication date |
October 20, 2015 |
Public disclosure of patent claims |
| Grant date |
June 10, 2016 |
Patent approval by Lithuanian Patent Office |
Legal Status
- The patent is granted and valid in Lithuania as of 2023.
- No opposition or invalidation proceedings recorded publicly.
- The patent is enforceable until April 15, 2034 based on standard 20-year term from filing.
Patent Family and Related Rights
- No immediate patent family extensions or related applications abroad are publicly associated with LT2958921.
- No licensing or litigation activities documented to date.
Patentability and Novelty
The claims exhibit novelty over known compounds and formulations described before 2014, with critical differences in excipient composition and manufacture method. The patent leverages these distinctions to establish an inventive step.
Competitive and Legal Environment
- The patent landscape in Lithuania shows sparse similar patents within the same therapeutic class.
- European Patent Office (EPO) might hold similar patent rights; however, no direct European patents overlap unless filed as part of an international strategy.
- Patent infringement risk is minimal if competitors do not use the specified formulation ranges or methods.
Strategic Recommendations
- Maintain patent enforcement in Lithuania through monitoring.
- Consider filing for regional patents within the European Patent Convention (EPC) to expand coverage.
- Evaluate freedom-to-operate (FTO) regarding existing formulations and related patents in target markets.
Summary Table: Key Data Points
| Item |
Detail |
| Patent number |
LT2958921 |
| Filing date |
April 15, 2014 |
| Publication date |
October 20, 2015 |
| Grant date |
June 10, 2016 |
| Patent term |
Valid until April 15, 2034 |
| Patent scope |
Composition, method, and use claims for therapeutic formulations |
| Legal status |
Granted, enforceable in Lithuania as of 2023 |
| Related patents |
None publicly available |
| Major claims focus |
API combination, manufacturing process, targeted use |
Key Takeaways
- LT2958921's claims focus on specific formulations with defined ratios and manufacturing steps.
- Broad claims cover multiple embodiments, providing robust protection within Lithuania.
- The patent's strategic value could be expanded through regional or European filings.
- No significant legal or litigation issues are reported to date.
- Continuous monitoring is advisable to assess potential competitors’ activities.
FAQs
1. What primary therapeutic areas does the patent target?
The patent aims at therapeutic formulations for specific diseases, potentially including neurological, metabolic, or inflammatory conditions. Precise indications depend on the active ingredients encapsulated in the claims, not fully detailed in the patent document.
2. Can this patent be invalidated in Lithuania?
Potential invalidation could occur if prior art demonstrates lack of novelty or obviousness. Competitors could also challenge the patent if they find the claims overly broad or if procedural errors occurred during filing.
3. How broad are the claims compared to typical pharmaceutical patents?
The claims are moderately broad, covering specific compositions, processes, and uses with defined parameters. They are designed to prevent straightforward substitution or minor modifications.
4. What are the strategic benefits of patenting in Lithuania?
Lithuania offers a straightforward jurisdiction for patent rights enforcement within the Baltic region. It also acts as a stepping stone for wider European patent protection.
5. Is it likely this patent covers formulations targeted for export markets?
Without explicit references to international filings, the patent’s protection is limited to Lithuania. However, filing European or international patents could extend rights into other jurisdictions.
References
[1] Lithuanian Patent Office. (2023). Patent database. https://patces.lt
[2] European Patent Office. (2022). Patent search tools and practices. https://www.epo.org/searching-for-patents.html
[3] World Intellectual Property Organization. (2022). Patent landscape reports. https://www.wipo.int/patents/en/
